Contrasting Adverum Biotechnologies (ADVM) and Rubius Therapeutics (RUBY)

Adverum Biotechnologies (NASDAQ:ADVM) and Rubius Therapeutics (NASDAQ:RUBY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings and valuation.

Valuation & Earnings

This table compares Adverum Biotechnologies and Rubius Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adverum Biotechnologies $1.85 million 160.56 -$56.14 million N/A N/A
Rubius Therapeutics N/A N/A -$43.84 million N/A N/A

Rubius Therapeutics has lower revenue, but higher earnings than Adverum Biotechnologies.


This table compares Adverum Biotechnologies and Rubius Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adverum Biotechnologies -3,582.48% -30.38% -28.67%
Rubius Therapeutics N/A N/A N/A

Analyst Ratings

This is a summary of recent ratings and target prices for Adverum Biotechnologies and Rubius Therapeutics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adverum Biotechnologies 0 4 1 0 2.20
Rubius Therapeutics 0 0 4 0 3.00

Adverum Biotechnologies presently has a consensus price target of $6.88, indicating a potential upside of 46.28%. Rubius Therapeutics has a consensus price target of $37.00, indicating a potential upside of 146.34%. Given Rubius Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Rubius Therapeutics is more favorable than Adverum Biotechnologies.

Insider and Institutional Ownership

55.8% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 82.6% of Rubius Therapeutics shares are owned by institutional investors. 5.0% of Adverum Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


Rubius Therapeutics beats Adverum Biotechnologies on 8 of the 10 factors compared between the two stocks.

Adverum Biotechnologies Company Profile

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage. It has collaboration agreement with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets, as well as includes AVA-311 for the treatment of juvenile X-Linked Retinoschisis. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Rubius Therapeutics Company Profile

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.

Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with's FREE daily email newsletter.